Biostatistical considerations in development of biomarker-based tests to guide treatment decisions

Statistics in Biopharmaceutical Research

Volumn 3, Issue 4, 2011, Pages 549-560

  Clark, Gary M ^a   McShane, Lisa M ^b  

^a ARRAY BIOPHARMA INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Assay qualification; Clinical trial design; Marker; Predictive marker; Prognostic marker

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BAYES THEOREM; BIOSTATISTICS; CLINICAL DECISION MAKING; FOOD AND DRUG ADMINISTRATION; HUMAN; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STUDY DESIGN; VALIDATION STUDY;

EID: 84867133676     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1198/sbr.2011.09038     Document Type: Article

References (31)

1. Altman, D.G., Lausen, G., Sauerbrei, W., and Schumacher, M. (1994), "Dangers of Using 'Optimal' Cutpoints in the Evaluation of Prognostic Factors, " Journal of the National Cancer Institute, 86, 829-835. 557
2. Andre, F., McShane, L.M., Michiels, S., Ransohoff, D.F., Altman, D.G., Reis-Filho, J.S., Hayes, D.F., and Pusztai, L. (2011), "Biomarker Studies: A Call for a Comprehensive Biomarker Study Registry, " Nature Reviews Clinical Oncology, 8, 171-176. 558
3. Berry, D.A. (2006), "Bayesian Clinical Trials, " Nature Reviews Drug Discovery, 5, 27-36. 558
4. Berry, D.A. (2011), "Adaptive Clinical Trials: The Promise and the Caution, " Journal of Clinical Oncology, 29, 606-609. 556
5. Booth, C.M., Calvert, A.H., Giaccone, G., Lobbezoo, M.W., Eisenhauer, E.A., and Seymour, L.K. (2008), "Design and Conduct of Phase II Studies of Targeted Anticancer Therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT), " European Journal of Cancer, 44, 25-29. 553
6. Clark, G.M., Zborowski, D.M., Culbertson, J.L., Whitehead, M., Savoie, M., Seymour, L., and Shepherd, F.A. (2006), "Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib, " Journal of Thoracic Oncology, 1, 837-846. 553
7. Clark, G.M., Zborowski, D., Santabarbara, P., Ding, K., Whitehead, M., Seymour, L., and Shepherd, F.A. (2006), "Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non-small Cell Lung Cancer in NCIC CTG Study BR.21, " Clinical Lung Cancer, 7, 389-394. 554
8. Clark, G.M. (2008), "Prognostic Factors Versus Predictive Factors: Examples From a Clinical Trial of Erlotinib, " Molecular Oncology, 1, 406-412: DOI: 10.1016/j.molonc.2007.12.001. 554
9. FDA Center for Devices and Radiological Health (2010), "Guidance for Industry and FDA Staff: Guidance for the use of Bayesian Statistics in Medical Device Clinical Trials, " available online at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071072.htm.Accessed 25 March 2011. 558
10. FDA Center for Devices and Radiological Health (2007), "Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests, " available online at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocumentsfucm071148.htm.Accessed 25 March 2011. 550, 551
11. Fox, E., Curt, G.A., and Balis, F.M. (2002), "Clinical Trial Design for Target-Based Therapy, " Oncologist, 7, 401-409. 552
12. Freidlin, B., and Korn, E.L. (2010), "Biomarker-Adaptive Clinical Trial Designs, " Pharmacogenomics, 11, 1679-1682. 556, 558
13. Freidlin, B., McShane, L.M., and Korn, E.L. (2010), "Randomized Clinical Trials with Biomarkers: Design Issues, " Journal of the National Cancer Institute, 102, 152-160. 554
14. Freidlin, B., and Simon, R. (2005), "Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing a Gene Expression Signature for Sensitive Patients, " Clinical Cancer Research, 11, 7872-7878. 557
15. Goulart, B.H.L., Clark, J.W., Pien, H.H., Roberts, T.G., Finkelstein, S.N., and Chabner, B.A. (2007), "Trends in the Use and Role of Biomarkers in Phase I Oncology Trials, " Clinical Cancer Research, 13, 6719-6726. 553
16. Jiang, W., Freidlin, B., and Simon, R. (2007), "Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment with Possible Biomarker-Defined Subset Effect, " Journal of the National Cancer Institute, 99, 1036-1043. 556, 557, 558
17. Korn, E.L., and Freidlin, B. (2011a), "Outcome-Adaptive Randomization: Is it Useful?, " Journal of Clinical Oncology, 29, 771-776. 556
18. Korn, E.L., and Freidlin, B. (2011b), Reply to Y. Yuan et al., Journal of Clinical Oncolology, available online at http://jco.ascopubs.org/content/29/13/e393.full, DOI: 10.1200/JC0.2011.34.6726. 556
19. McShane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M., and Clark, G.M.; Statistics Subcommittee of the NCIC-EORTC Working Group on Cancer Diagnostics (2005), "REporting recommendations for Tumor MARKer Prognostic Studies (REMARK), " Journal of the National Cancer Institute, 97, 1180-1184. 558
20. McShane, L.M., Hunsberger, S., and Adjei, A.A. (2009), "Effective Incorporation of Biomarkers into Phase II Trials, " Clinical Cancer Research, 15, 1898-1905. 553
21. Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., and Fukuoka, M. (2009), "Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma, " New England Journal of Medicine, 361, 947-957. 554
22. Ratain, M.J., and Glassman, R.H. (2007), "Biomarkers in Phase I Oncology Trials: Signal, Noise or Expensive Distraction?, " Clinical Cancer Research, 13, 6545-6548. 553
23. Sargent, D., and Allegra, C. (2002), "Issues in Clinical Trial Design for Tumor Marker Studies, " Seminars in Oncology, 22, 222-230. 555
24. Shoukri, M.M. (1998), "Agreement, Measurement of, " in Encyclopedia of Biostatistics, eds. P. Armitage and T. Colton, New York: Wiley. 550
25. Simon, R., and Maitournam, A. (2004), "Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials, " Clinical Cancer Research, 10, 6759-6763. 553
26. The BUGS Project (2011), http://www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml. Accessed 20 March 2011. 559
27. Twombly, R. (2006), "Slow Start to Phase 0 as Researchers Debate Value, " Journal of the National Cancer Institute, 98, 904-906. 553
28. Wagner, J.A., Williams, S.A., and Webster, C.J. (2007), "Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs, " Clinical Pharmacology and Therapeutics, 81, 104-107. 549
29. Weissler, A.M., and Bailey, K.R. (2004), "A Critique on Contemporary Reporting of Likelihood Ratios in Test Power Analysis, " Mayo Clinic Proceedings, 79, 1317-1318. 552
30. Yuan, Y., and Yin, G. (2010), "On the Usefulness of Outcome-Adaptive Randomization, " Journal of Clinical Oncology, available online at http://jco.ascopubs.org/content/29/13/e390.full, DOI: 10.1200/JCO.2010.34.5330. 556
31. Zweig, M.H., and Campbell, G. (1993), "Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine, " Clinical Chemistry, 39, 561-577. 551